Last reviewed · How we verify
Mitomycin (MM)
Mitomycin is an antibiotic that alkylates DNA, causing cross-linking and strand breaks that prevent cell division and induce apoptosis.
Mitomycin is an antibiotic that alkylates DNA, causing cross-linking and strand breaks that prevent cell division and induce apoptosis. Used for Gastric cancer, Colorectal cancer, Bladder cancer.
At a glance
| Generic name | Mitomycin (MM) |
|---|---|
| Sponsor | University of Sydney |
| Drug class | Antibiotic alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mitomycin acts as a DNA-damaging agent by forming covalent cross-links between DNA strands after bioreductive activation. This prevents DNA replication and transcription, leading to cell cycle arrest and programmed cell death. It is primarily used in cancer therapy due to its potent cytotoxic effects on rapidly dividing cells.
Approved indications
- Gastric cancer
- Colorectal cancer
- Bladder cancer
- Breast cancer
Common side effects
- Myelosuppression (bone marrow suppression)
- Nausea and vomiting
- Hemolytic uremic syndrome
- Pulmonary toxicity
- Nephrotoxicity
Key clinical trials
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (PHASE1)
- Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG (NA)
- Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer (PHASE3)
- A Comparative Study of Endoscopic Choanal Canalization and Mitomycin C Application vs Endoscopic Crossover Flap Technique (NA)
- Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain (NA)
- BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer (PHASE3)
- Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer (PHASE3)
- Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin (MM) CI brief — competitive landscape report
- Mitomycin (MM) updates RSS · CI watch RSS
- University of Sydney portfolio CI